Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lucentis for Scotoma Reduction in Advanced Wet AMD
NCT00467935Phase 2Completed
- Sponsor
- Retina Research Foundation
- Start
- Mar 2007
- Primary completion
- Nov 2007
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ranibizumab in neovascular age-related macular degeneration (nAMD), sponsored by Retina Research Foundation. Started Mar 2007; status: completed.
02
Drugs
ranibizumab
03
Conditions
neovascular age-related macular degeneration (nAMD)
Beyond the preview
Go deeper on NCT00467935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00467935.